GLP-1 Compounding After Drug Shortages

FDA Shortage Resolution Triggers Legal Reckoning for Compounded GLP-1 Drugs

The regulatory status of compounded versions of popular GLP-1 receptor agonists like semaglutide and tirzepatide remains a contentious legal issue following the Food and Drug Administration's determination that shortages of the underlying drugs have been resolved. According to an analysis published by The Regulatory Review, the shift from shortage to supply-adequate status has triggered significant regulatory and legal consequences for compounding pharmacies that scaled up production during the shortage period.

The Regulatory Review's coverage highlights a central tension in pharmaceutical regulation: compounding pharmacies are permitted under federal law to produce copies of FDA-approved drugs when those drugs appear on the agency's official shortage list, but that exemption evaporates once the FDA declares the shortage over—even as compounders and patient advocates dispute whether supply is truly adequate on the ground.

Background: How the Shortage Exemption Worked

Under the Federal Food, Drug, and Cosmetic Act, compounding pharmacies operating under Section 503A and outsourcing facilities registered under Section 503B are generally prohibited from producing compounded versions of commercially available drugs. However, when the FDA lists a drug as being in shortage, compounders may legally produce "essentially copies" of that medication to fill gaps in patient access.

This exemption became enormously significant during the GLP-1 shortage that began in 2022, as demand for semaglutide (marketed as Ozempic and Wegovy by Novo Nordisk) and tirzepatide (marketed as Mounjaro and Zepbound by Eli Lilly) surged beyond manufacturers' production capacity. Thousands of compounding pharmacies entered the market, offering lower-cost alternatives to patients who could not access or afford the brand-name products.

• The FDA removed tirzepatide from its drug shortage database in December 2024
• Semaglutide was similarly declared no longer in shortage in February 2025
• Both determinations ended the broad legal basis for mass compounding of these medications
• Compounders faced compressed timelines to wind down production under FDA guidance

Why This Matters for the Peptide and Compounding Industry

The resolution of the shortage designation represents one of the most consequential regulatory developments for the compounding industry in recent memory. Compounding pharmacies had built substantial business lines—and in some cases entire companies—around producing lower-cost GLP-1 alternatives. The end of the shortage exemption forces an abrupt business model shift.

The Regulatory Review's discussion of this issue underscores that the stakes extend beyond individual pharmacies. Telehealth platforms, specialty clinics, and med-spa operators that built patient acquisition funnels around compounded GLP-1 products now face existential questions about their continued ability to offer these treatments, absent patient-specific clinical justifications recognized under compounding law, such as documented allergies to inactive ingredients in the FDA-approved formulations.

Industry groups, including the Outsourcing Facilities Association, have pushed back against the FDA's shortage-resolution determinations, arguing that the agency's data does not reflect persistent access and affordability barriers that many patients continue to experience. This dispute has already generated litigation, with compounders arguing that the FDA's process for declaring shortages resolved lacks adequate transparency and fails to account for real-world market conditions.

Regulatory Implications Explained

For readers unfamiliar with the compounding framework, the core legal issue is straightforward but consequential: the shortage list functions as a regulatory on-off switch for a significant portion of the compounding industry's product offerings.

When a drug is on the shortage list, compounders enjoy relatively broad latitude to produce copies. When a drug comes off that list, compounders must generally stop producing identical copies, though limited exceptions remain for legitimate, documented clinical need on a patient-by-patient basis. This is not the same as the mass-market compounding that characterized the GLP-1 shortage era.

The FDA has signaled it intends to enforce this transition, having issued guidance documents outlining expected wind-down periods for 503A and 503B facilities. However, enforcement consistency and timelines have varied, and some compounders have continued offering products under legal theories involving personalized dosing or alternative formulations not identical to the brand-name products.

What This Means for Patients and Industry Stakeholders

• Patients currently using compounded semaglutide or tirzepatide should expect reduced access through standard compounding channels and may face higher costs if transitioning to brand-name products.
• Compounding pharmacies face heightened FDA scrutiny and potential enforcement action if they continue mass-producing essentially-copy formulations without proper legal basis.
• Telehealth companies built around GLP-1 prescribing models must reassess their supply chains and legal compliance posture.
• Manufacturers like Novo Nordisk and Eli Lilly stand to benefit from reduced compounded competition, though both companies have also pursued direct litigation against compounders independent of the shortage issue.

What to Watch For

Several developments bear close monitoring in the coming months. Litigation challenging the FDA's shortage-resolution determinations remains pending in multiple jurisdictions, and outcomes could either reaffirm or undermine the agency's authority to make these calls unilaterally. Additionally, state pharmacy boards may take independent enforcement positions that diverge from federal guidance, creating a patchwork regulatory landscape.

Readers should also watch for potential Congressional interest in the broader compounding framework, as lawmakers from both parties have previously expressed interest in revisiting compounding law in light of the GLP-1 episode. The Regulatory Review's continued coverage of this issue will likely remain a valuable resource for tracking these developments.

This article is for informational purposes only and does not constitute legal or medical advice. Readers with specific questions about compounded medications should consult a licensed healthcare provider or attorney specializing in FDA regulatory law.